

# Bavencio (avelumab)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Bavencio (avelumab)

## **APPROVAL CRITERIA**

Requests for Bavencio (avelumab) may be approved if the following criteria are met:

- I. Individual has a diagnosis of metastatic Merkel cell carcinoma (Label, NCCN 2A); **AND**
  - A. Individual is 12 years of age or older; **AND**
  - B. Individual has a current Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; **AND**
  - C. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**
  - D. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant;

**OR**

- II. Individual has a diagnosis of locally advanced or metastatic Urothelial Carcinoma (Label, NCCN 1); **AND**
  - A. Individual is using as monotherapy; **AND**
  - B. Individual has a current ECOG performance status of 0-2; **AND**
  - C. Individual meets **one** of the following criteria:
    1. Individual is using after platinum-containing chemotherapy (either as subsequent therapy after disease progression during or following platinum regimen, **or** as maintenance therapy following completion of platinum regimen with no evidence of disease progression); **OR**
    2. Has demonstrated disease progression within 12 months of receiving neoadjuvant or adjuvant treatment with platinum-containing chemotherapy;
  - AND**
  - D. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**
  - E. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant;

**OR**

- III. Individual has a diagnosis of multi-agent chemotherapy-resistant gestational trophoblastic neoplasia (NCCN 2A); **AND**
  - A. Individual has intermediate OR high-risk disease; **AND**
  - B. Individual is using as single-agent therapy; **AND**
  - C. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**

D. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant;

**OR**

- IV. Individual has a diagnosis of endometrial carcinoma (NCCN 2A); **AND**
- A. Individual is using for recurrent or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors; **AND**
  - B. Individual is using as monotherapy; **AND**
  - C. Individual is using as second-line treatment or subsequent therapy; **AND**
  - D. Individual has a current ECOG performance status of 0-2; **AND**
  - E. Individual has not received treatment with another anti-PD1 or anti-PD-L1 agent; **AND**
  - F. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant;

**OR**

- V. Individual has a diagnosis of advanced Renal Cell Carcinoma (RCC) (Label, NCCN 2A); **AND**
- A. Individual is using as first-line therapy; **AND**
  - B. Individual is using in combination with axitinib (Inlyta); **AND**
  - C. Individual has histological confirmation of RCC with clear cell component; **AND**
  - D. Individual has an ECOG performance status of 0-2; **AND**
  - E. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**
  - F. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant.

Requests for Bavencio (avelumab) may not be approved when the above criteria are not met and for all other indications.

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 9, 2024
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on December 30, 2023.
  - a. Bladder Cancer. V3.2023. Revised May 25, 2023.
  - b. Gestational Trophoblastic Neoplasia. V1.2024. Revised October 24, 2023.
  - c. Kidney Cancer. V2.2024. Revised January 3, 2024.
  - d. Merkel Cell Carcinoma: V1.2024. Revised November 22, 2023.
  - e. Uterine Neoplasms. V1.2024. Revised September 20, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.